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and transcellular permeation of the lipophilic
drug diazepam in pregnant women
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and Momir Mikov4,5,7Abstract
Background: Previous studies carried out in our laboratories have demonstrated impaired drug permeation in
diabetic animals. In this study the permeation of diazepam (after a single dose of 5 mg/day, administered
intramuscularly) will be investigated in diabetic and hypertensive pregnant women.
Methods: A total 75 pregnant women were divided into three groups: group 1 (healthy control, n = 31), group 2
(diabetic, n = 14) and group 3 (hypertensive, n = 30). Two sets of diazepam plasma concentrations were collected
and measured (after the administration of the same dose of diazepam), before, during and after delivery. The first
set of blood samples was taken from the mother (maternal venous plasma). The second set of samples was taken
from the fetus (fetal umbilical venous and arterial plasma). In order to assess the effect of diabetes and
hypertension on diazepam placental-permeation, the ratios of fetal to maternal blood concentrations were
determined. Differences were considered statistically significant if p ≤ 0.05.
Results: The diabetes and hypertension groups have 2-fold increase in the fetal umbilical-venous concentrations,
compared to the maternal venous concentrations. Feto: maternal plasma-concentrations ratios were higher in
diabetes (2.01 ± 1.10) and hypertension (2.26 ± 1.23) groups compared with control (1.30 ± 0.48) while, there was no
difference in ratios between the diabetes and hypertension groups. Umbilical-cord arterial: venous ratios (within
each group) were similar among all groups (control: 0.97 ± 0.32; hypertension: 1.08 ± 0.60 and diabetes: 1.02 ± 0.77).
Conclusions: On line with our previous findings which demonstrate disturbed transcellular trafficking of lipophilic
drugs in diabetes, this study shows significant increase in diazepam placental-permeation in diabetic and
hypertensive pregnant women suggesting poor transcellular control of drug permeation and flux, and bigger
exposure of the fetus to drug-placental transport.
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The development and progression of diabetes have been
associated with disturbed drug absorption due to dys-
functional protein expression and functionality, impaired
transcellular transport and intercellular trafficking as
well as altered gut physiology [1].
Due to the widespread rise in early detection of high-
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distribution, and reproduction in any mediumrapidly increasing worldwide. High-risk pregnant women
include those with uncontrolled diabetes, hypertension
and pre-eclampsia [2-4]. Diazepam is used in the treat-
ment of maternal eclampsia and as a premedication
in cesarean section deliveries. It is highly lipophilic
drug with linear pharmacokinetics [5]. Diazepam readily
crosses the blood–brain barrier and the placenta by pas-
sive diffusion. It is also excreted into breast milk and re-
cent studies show that diazepam reaches equilibrium in
the feto-maternal systemic circulation 10-15 minutes
after intravenous administration [6].entral Ltd. This is an open access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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properties of the drug; protein binding and state of pla-
cental barrier (i.e. blood flow). Some diseases such as
diabetes and hypertension have been associated to im-
paired placental composition and functions. Moreover,
pregnancy in diabetic and hypertensive women is dir-
ectly linked to increased fetal morbidity and mortality
[7-9]. These may be in a part related to changes in pla-
cental transport of maternal nutrients to the fetus and
consequent abnormal placental development [10-13].
Placental dysfunction may result from a reduced placen-
tal blood flow and placental infarctions [14,15].
Despite the fact that diazepam has been used for many
years in pregnancy, its direct placental permeation, in
diabetic and hypertensive pregnant women, remains
poorly understood. Thus the purpose of this study is to
investigate the influences of diabetes and hypertension
on the transplacental permeation of diazepam, after
intramuscular injection to pregnant women.
Methods
Subjects
Pregnant women were recruited from the Gynecology
and Obstetric clinic of Vojvodina (Serbia). Pregnant
women scheduled for cesarean section, those who were
diagnosed with gestational or arterial hypertension [16]
as well as those who were diagnosed gestational diabetes
[17] were included in this study. A total of 75 pregnant
women were divided into three groups: healthy control
group (n = 31), diabetes group (n = 14) and hypertension
group (n = 30). Gestational or arterial hypertension was
diagnosed according to The Good Clinical Practice
National Guidelines on Diagnostic and Treatment of
Arterial Hypertension [16]. Gestational diabetes mellitus
was diagnosed according to The Good Clinical Practice
National Guidelines on Diabetes Mellitus [17]. Three
women in diabetes group were receiving insulin and the
rest were on diabetes diet. The women in hypertension
group were on methyldopa regular dosing. Prior to en-
rolment into the study, medical history was taken and a
physical examination was performed. Only women withTable 1 Summary of a) feto: maternal diazepam plasma conc
diazepam plasma concentration ratios (Ca/Cv), and c) times o
deviation (min-max))
Number of women [N = 75] Control group [n = 31]
Cv/Cm 1.30 ± 0.48 (0.59–2.27)
Ca/Cv 0.97 ± 0.32 (0.1–1.60)
t1 (min) 25.9 ± 21.51 (5–118)
t2 (min) 60.23 ± 31.87 (18–144)
t3 (min) 132.39 ± 42.07 (67–230)
#control group vs. hypertension group, p ≤ 0.05.
##control group vs. diabetes group, p ≤ 0.05.normal renal and liver function were included. Diazepam
was applied by intramuscular injection (i.m.; 5 mg/day)
into gluteal muscle of mothers. Maternal demographic
data (i.e. age, height and weight) and neonatal birth
weight, length and 1st and 5th minute Apgar scores were
taken. The study protocol was approved by Ethic
Committee of the Gynecology and Obstetistric clinic in
Vojvodina (N°00-08/9) and informed consents were
obtained from each participant before inclusion in the
study. Before the cesarean section, a spinal anaesthesia
with 0.5% bupivacaine hydrochloride or a general anaes-
thesia with propofol, succinylcholine and fentanyl were
applied as a part of the clinic common procedures.
Spinal anaestheisa was applied to 11 women in the con-
trol group, 2 women in the diabetes group and 3 women
in the hypertension group. General anaesthesia was ap-
plied to 20 women in the control group, 27 women in
the hypertension group and 12 women in the diabetes
group.
Sample collection
Maternal peripheral venous blood samples (2 mL) were
collected from the arm using an indwelling cannula.
Three samples were collected from all mothers. First
sample was taken after application of diazepam and be-
fore cesarean section (time t1). Second sample of mater-
nal blood was taken at the same time with clamping of
the infant’s umbilical cord (time t2). Third sample was
taken after cesarean section (time t3). Times t1, t2 and t3
are presented in Table 1. Neonatal umbilical cord venous
and arterial samples were obtained from a section of
umbilical cords, cross clamped at delivery. Blood sam-
ples were collected in a vacutainer containing EDTA.
Sample extraction
Plasma was transferred to plastic tubes after centrifugation
and frozen at -20°C prior to analysis. Diazepam from
plasma samples was extracted by liquid-liquid extraction.
To 0.5 mL of plasma sample was added 0.5 mL of mixture
of 5 M sodium hydroxide and 3 M sodium chloride. Mix-
ture was vortexed for 30 seconds and then added 2.5 mLentration ratios (Cv/Cm); b) umbilical cord arterial: venous
f sample collection t1, t2 and t3 (min) (mean ± standard
Hypertension group [n = 30] Diabetes group [n = 14]
2.26 ± 1.23 (0.25–4.21)# 2.01 ± 1.10 (0.42–3.77) ##
1.08 ± 0.60 (0.33–2.50) 1.02 ± 0.77 (0.17–2.97)
28.70 ± 18.18 (10–93) 20.31 ± 11.84 (7–42)
64.37 ± 22.69 (25–114) 45.38 ± 30.25 (18–138)
130.40 ± 39.90 (76–278) 122.38 ± 22.61 (92–172)
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sample was centrifuged 10 minutes at 3500 rpm (2100
rcf), 1.5 mL of the lower layer was transferred to glass
tubes, evaporated at 60°C and before injection to HPLC
system reconstituted with 100 μl of mobile phase. A 20 μl
of sample was injected into HPLC system.
Sample analysis
Diazepam concentrations in plasma were measured by
modified HPLC method previously described [18]. HPLC
system (Dionex) consisted of Agilent column (5 μm,
100 mm × 2.1 mm) with guard column (Agilent; 5 μm,
20 mm × 2.1 mm). Mobile phase was consisted of 50 mM
potassium dihydrogen phosphate buffer (pH 3) and
acetonitril in ration 65:35 (v/v), at flow rate 0.4 mL/min.
Retention time for diazepam was 7.5 minutes. UV detec-
tion was set at 230 nm. Analyses were done at room
temperature (25°C). The limit of detection (LOD) was
0.005 μg/mL and limit of quantification (LOQ) 0.01 μg/
mL with recovery of 94.33 ± 2.12. The calibration curve
was linear in the concentration range of 0.01-10 μg/mL.
Statistical analysis
All data were measured as mean ± standard deviation
(SD). Data were analyzed using one way analysis of vari-
ance (ANOVA) and the means were compared using
Tukey`s test (P ≤ 0.05) via SPSS 17.0 (Systat Software
Inc., San Jose, CA). Differences were considered signifi-
cant if p ≤ 0.05. Areas under the curve (AUC) were cal-
culated by trapezoidal method using WinNon-
Lin (version 4.1; SCI software, Pharsight Corp., Gary
NC, USA). Feto: maternal concentration ratios (cv/cm)
were calculated by dividing diazepam concentrations in
neonatal umbilical venous blood by concentrations in
maternal venous blood. Also umbilical cord arterials to
umbilical cord venous concentration ratios (ca/cv) wereTable 2 Summary of demographic characteristics of mothers
Number of women [N = 75] Control group [n = 31]
Age [years] 31.03 ± 4.13 (23-40)
Height [m] 1.65 ± 0.078 (1.52–1.81)
Weight [kg] 79.97 ± 14.09 (60–136)
BSA [m2]* 1.87 ± 0.23 (1.09–2.59)
BMI [kg/m2]** 29.69 ± 6.65 (18.87–41.51)
Systolic pressure (mmHg) 111.3 ± 11.9 (90–130)
Diastolic pressure (mmHg) 70.6 ± 8.5 (60–80)
Dose (mg/kg) 0.063 ± 0.0084 (0.04–0.08)
Dose (mg/m2) 2.66 ± 0.23 (1.93–3.12)
*Boyd ’ s equation BSA = 0.000327 * weight(g)(0.7285 − 0.0188 log10 weight(g)) * hei
** BMI –body mass index; BMI = weight (kg)/height (m2).
#control group vs. hypertension group, p ≤ 0.05.
Δhypertension group vs. diabetes group, p ≤ 0.05.determined as a measure of diazepam uptake, distribu-
tion and/or metabolism in neonates.
Results
Demographic characteristics
There were total 75 women included in the study sched-
uled for cesarean section. All women went through
normal pregnancy and gave birth to healthy single new-
borns. The age of included women was between 20 and
42 years. There were no statistically significant differ-
ences neither in height, weight nor body surface area
(BSA; m2) of the women between three investigated
groups (Table 2). Also, doses of diazepam normalized
per body mass (mg/kg) and BSA (mg/m2) were not sta-
tistically different between groups (Table 2). However,
systolic and diastolic pressures were statistically signifi-
cantly higher in hypertension group compared to dia-
betes and control group as expected. All women in
hypertension group were receiving methyldopa (250 mg)
and in diabetes group 3 women were receiving insulin
and the rest were on diabetes diet.
All neonates were similar in length, weight and BSA
(Table 3). Also Apgar scores for all the newborn babies,
measured in 1st and 5th minute after birth, were mostly
normal. In control group there were 2 neonates with 1st
minute Apgar score 6 and one neonate with 1st minute
Apgar score 5. Also, one newborn infant in the group of
women with diabetes had 1st minute Apgar score 6 and
two neonates in group of women with hypertension had
1st minute Apgar score 5. All neonates had 5th minute
Apgar score 7 or above. Statistically significant differ-
ences were observed in gestational age of children,
where children in hypertension and diabetes group of
women were delivered earlier. Transfer of diazepam
starts from 6th week of gestation and further its transfer
is not dependant on gestational age thus the differencesand dosage details (mean ± standard deviation (min-max)
Hypertension group [n = 30] Diabetes group [n = 14]
N = 30 N = 14
33.87 ± 5.72 (20-42) 32.14 ± 5.79 (24-41)
1.66 ± 0.059 (1.51–1.80) 1.65 ± 0.065 (1.53–1.78)
95.71 ± 22.69 (51–142) 87.00 ± 21.51 (60–127)
2.087 ± 0.28 (1.48–2.62) 1.97 ± 0.27 (1.61–2.45)
32.66 ± 7.74 (19.2–43.2) 30.77 ± 7.47 (18.37–42.47)
150.0 ± 14.3 (130–180) # 120.0 ± 16.4 (90–150)Δ
96.7 ± 8.8 (80–120) # 73.6 ± 9.3 (60–90) Δ
0.057 ± 0.014 (0.04–0.10) 0.061 ± 0.014 (0.04–0.08)
2.45 ± 0.35 (1.91–3.38) 2.58 ± 0.36 (2.04–3.11)
ght(cm).
Table 3 Summary of demographic characteristics of neonates and Apgar scores (mean ± standard deviation (min-max))
Number of women [N = 75] Control group [n = 31] Hypertension group [n = 30] Diabetes group [n = 14]
Length [cm] 49.84 ± 1.97 (45–53) 48.43 ± 3.03 (42–53) 49.43 ± 3.95 (41–54)
Weight [kg] 3.49 ± 0.51 (2.27–4.54) 3.12 ± 0.88 (1.73–4.65) 3.54 ± 0.75 (1.83–4.50)
BSA [m2]* 0.22 ± 0.0.02 (0.10–0.17) 0.21 ± 0.04 (0.13–0.14) 0.23 ± 0.03 (0.13–0.14)
Apgar score (1 min) 8.97 ± 1.36 (5–10) 7.9 ± 1.33 (5–10) 8.79 ± 1.26 (6–10)
Apgar score (5 min) 9.58 ± 0.83 (7–10) 8.83 ± 0.90 (7–10) 9.43 ± 0.82 (7–10)
Gestational age (weeks) 39.6 ± 0.8 (39–42) 37.9.1 ± 2.38 (32–41) # 38.3 ± 0.81 (37–39) ##
Neonatal gender (Male/Female) 14/17 22/8 8/6
#control group vs. hypertension group, p ≤ 0.05.
##control group vs. diabetes group, p ≤ 0.05.
*Boyd ’ s equation BSA = 0.000327 * weight (g) (0.7285 − 0.0188 log10 weight (g)) * height (cm).
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not influence diazepam transfer [19].
Pharmacokinetic analyses
The concentrations of diazepam (μg/mL) in the mater-
nal plasma (cm) and neonatal plasma at delivery (venous
umbilical cord plasma cv and arteriala umbilical cord
plasma ca) are shown in Figure 1. The corresponding
feto: maternal plasma concentration ratios (cv/cm) and
umbilical arterial: venous plasma ratios (ca/cv) are shown
in Table 1. In the control group fetal diazepam concen-
trations were higher than maternal diazepam concentra-
tions in 71% of cases (feto: maternal ratios > 1), while inFigure 1 Box plots of diazepam concentrations (μg/mL) in maternal v
arterial umbilical cord (Ca) plasma at delivery [black stars represent ehypertension group there were 80% of feto: maternal
ratios higher than 1 and in diabetes group there were
78% feto: maternal ratios higher than 1. Maternal diaze-
pam concentrations were statistically higher in control
(0.09 ± 0.06 μg/mL) and hypertension group (0.07 ±
0.06 μg/mL) compared to group of women with diabetes
(0.02 ± 0.01 μg/mL). Group of women with hypertension
(0.12 ± 0.09 μg/mL) and control group (0.1 ± 0.05 μg/mL)
had statistically higher arterial umbilical cord diaze-
pam concentrations than group of women with dia-
betes (0.04 ± 0.03 μg/mL). There was statistically lower
diazepam umbilical venous concentration in diabetes
group (0.05 ± 0.04 μg/mL) compared to hypertensionenous plasma (Cm) and neonatal venous umbilical cord (Cv) and
xtreme cases and white circles are outlier values].
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0.06 μg/mL). In control group 45% of arterial: venous
cord ratios were over 1, while in diabetes and hypertension
group 50% of arterial: venous cord ratios were over 1,
where in hypertension group 13% and in diabetes group 7%
of ratios were over 2, which was not detected in control.
Study was approved under condition that it did not
disturb the regular clinical procedures, which resulted in
sampling times variability (Table 1). However, in this
study diazepam was applied by long needle (21 gauges,
40 mm) in the outer upper quadrant of the buttock by
which it was avoided fat tissues thus it was expected to
reach maximal concentrations after 0.30-1.30 hours
[20-22].
In Figure 2 are presented partial area under the curve
values (AUC; min*μg/mL) calculated from the zero time
to the time at delivery (AUC 0-t2) and from the delivery
time to the time of taken sample after cesarean section
(AUC t2-t3). Values of AUC before delivery were taken
as a measure of fetal exposure to diazepam. There were
statistically higher AUC values before delivery in control
and hypertension group compared to diabetes group.
Values of AUC after delivery were statistically higher in
control group compared to hypertension and diabetes
group, but there were no significant differences between
hypertension and diabetes group. Values of AUC afterFigure 2 Box plots of partial AUCs of diazepam in maternal venous p
from the time of delivery to the time of taken sample after cesarean
circles are outlier values].delivery were taken as a measure of diazepam elimination
from the blood.
Diazepam concentrations in umbilical cord venous
plasma, arterial cord plasma and maternal plasma were
correlated with each other and weight, height, BSA, AUC
and applied dose (Pearson’s coefficient of correlation were
calculated; r2). Diazepam concentrations in umbilical cord
venous plasma and concentrations in maternal venous
plasma were positively correlated in all three groups
(r2= 0.75 control group; r
2
= 0.80 diabetes group and r
2
= 0.77
hypertension group, but in hypertension group three pairs
were excluded from correlation). There were no correla-
tions between dose, AUC, BSA, BMI, weight and maternal
diazepam plasma concentrations at delivery (Cm) or cor-
relation between neonatal weight or BSA and umbilical
cord plasma concentrations.
Discussion
Main finding of this study is that feto: maternal ratios
were higher in hypertension and diabetes group
compared to control group. Maternal diazepam concen-
trations were statistically higher in control and hyperten-
sion group compared to group of women with diabetes.
Umbilical cord arterial: venous plasma concentration
ratios were similar in all groups and they were not statis-
tically different.lasma from the zero time to the time at delivery (AUC 0-t2) and
section (AUC t2-t3) [black stars represent extreme cases and white
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which did not disturb regular clinical procedures. Limi-
tation of this study is smaller number of pregnant
women in diabetes group than in control and hyperten-
sion group.
In a majority of previous studies diazepam umbilical
cord plasma concentrations exceeded maternal concen-
trations [23-25], although feto: maternal ratios below 1
have also been reported [26]. Diazepam is highly
liposoluble and crosses placenta by passive diffusion via
transcellular route [27,28] thus diazepam transfer de-
pends on properties of the placenta and is in a function
of multiple factors such as placental blood flow, protein
binding, lipid solubility and ionization constant (pKa).
In our study there were 76% of feto: maternal ratios
above and 24% of feto-maternal ratios below 1. There
were also feto-maternal ratios above 2 (16% control
group; 57% hypertension group; 36% diabetes group).
This study demonstrates that feto: maternal ratios in dia-
betes and hypertension groups were significantly higher
than in control. However, there was no difference be-
tween the ratios of the diabetes and hypertension
groups. Since the administered doses of diazepam were
similar in all groups, our findings show that there is a
difference in diazepam transfer across placenta in the
diabetes and hypertension groups.
There is no drug-drug interactions observed or
reported [29-32] between diazepam and other adminis-
tered drugs/anaesthetics, which indicates that diazepam
absorption studies were not compromised.
Since no known interaction on pharmacokinetic level
are expected between diazepam and insulin it was not
considered that insulin treatment in 3 women in dia-
betes group had effect on concentration data.
Interestingly, in one study, a single oral dose of 5 mg
diazepam taken before dental treatment did not influ-
ence blood glucose level in nondiabetic and non-insulin
dependent diabetic subjects [33]. But diazepam may alter
insulin secretion and insulin sensitivity after a single ad-
ministration in healthy volunteers [34], and diazepam-
induced hyperglycemia, might be related to changes in
serum chromium levels [35]. However in this study the
increase in glycemia in diabetic women would be the re-
sult of the stress due to operation rather than diazepam
treatment.
Binding of diazepam to human serum albumin can be
influenced by hypertension and diabetes due to changes
in hemodynamic properties or by drugs used for their
treatment. Since diazepam is highly bound to proteins
(96-99%), and protein bound fraction of drug do not
cross placenta [36], its metabolism rate and transplacen-
tal passage depends on free drug fraction. Diazepam is
more protein bound in fetal circulation than in maternal
circulation and it has one binding site on human serumalbumin [37]. Since there is no known interactions at the
level of protein binding between methyldopa or insulin
nor drugs used in anaesthesia, observed higher feto: ma-
ternal ratios in diabetes and hypertension group could be
consequence of the increased level of some endogenous
substance in diabetes and hypertension, like free fatty acid
which displace diazepam from proteins [38,39].
In the study by Ridd et al. [39] were found differences
in protein binding of diazepam in maternal and diaze-
pam plasma but free diazepam fractions were similar on
both sides of placenta. Unbound drug concentrations in
plasma are responsible for the obtained pharmacological
effects, thus it would be expected that partial displace-
ment of diazepam from plasma proteins would result in
the increase in the magnitude of its pharmacological ef-
fects [40-43]. In our study there were no side effects in
newborns (i.e. Apgar scores had normal values) or in
mothers but this does not imply that there were no in-
crease in diazepam free fraction. Since total clearance of
diazepam is directly proportional to free diazepam frac-
tion [44-46] and increased free diazepam fraction would
lead to higher elimination and disappearance of diaze-
pam from blood. This could be proved through AUC
values after delivery which were statistically higher in
control group compared to hypertension and diabetes
group that implies that elimination of diazepam from
central compartment is higher in hypertension and dia-
betes group and that is likely that there were more un-
bound diazepam in the blood in these groups.
Also other mechanisms such as metabolism and active
transport could lead to differences in feto: maternal unit.
Diazepam is metabolized by CYP enzymes some of
which are present in placenta like CYP3A4 [47]. Pres-
ence of CYP 3A4 in human placenta is more than con-
troversial, based on original and review articles [48],
although some expression may be present at a very low,
not functionally significant level. The most direct study
on the absence of CYP3A-catalyzed metabolism was
conducted on carbamazepine [49]. Previous studies
showed that diazepam is not substrate for P-glyco-
protein [50] but recent study suggested that diazepam is
a modifier of P-glycoprotein because it behaved as an ac-
tivator of the P-glycoprotein ATP-ase activity [51]. The
potential of diazepam to modify P-glycoportein could
affect placental transfer of other drugs which are
substrates of P-glycoprotein. Still observed higher trans-
placental transition of diazepam in diabetes and hyper-
tension group in our study may be due to lower activity
of some other efflux proteins.
Ionic composition of cellular and extracellular space is
altered in hypertension and diabetes due to altered work
of some ion exchange pumps like Na+/H+ and Ca2+/H+
[52,53]. This could have influence on degree of diazepam
ionization since if ionic strength of solution is lower
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diazepam is weak base (pKa 3.3), mainly unionized in
blood (pH 7.4) when unionized molecules leave plasma
balance is shifted to new ionization. Since fetal plasma is
slightly more acidic, 0.1 lower than maternal plasma pH,
the un-ionized free drug crossing the placenta becomes
ionized and is ‘trapped’ in the more acidic fetal circula-
tion [54,55]. In this study only in control group in all
cases umbilical cord arterial: venous diazepam plasma
concentration ratios were close to one, but in hyperten-
sion and diabetes group half of ratios were over one
which means that higher maintenance of diazepam oc-
curred within infants of mothers with diabetes or hyper-
tension. As it was single dose use of diazepam and
Apgar scores were not statistically different between
groups there were no observed differences in pharmaco-
logical effect on neonates between groups. Some studies
showed that maternal diazepam medication affects the
beat-to-beat variability in the newborns [56] but dur-
ation of the effect is more profound in the chronic and
infusion diazepam groups. However, it is known that
diazepam free fraction increases shortly after birth which
explains adverse effects observed clinically in some
diazepam exposed neonates [57]. Thus it could be
concluded that hypertensive and diabetic group neonates
were in higher risk of serious diazepam side effects.
Conclusions
As expected, our findings show significant and direct
effect of diabetes and hypertension development on
diazepam absorption kinetics and transcellular traffick-
ing across the placenta. On the other hand, the findings
do not show a significant difference between diabetes
and hypertension in diazepam placental-permeation.
This raises further questions on the suitability of lipo-
philic drugs in pregnancy and future short and long
term safety of the new born babies. Thus further studies
are necessary to determine whether other lipophilic
drugs also show such difference in placental-permeation.
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